A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab

Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC. Previous studies indicated biochemical and immunological improvement in PBC after rituximab...

Full description

Bibliographic Details
Main Authors:	Tajiri, Kazuto, Tsuneyama, Koichi, Miyazono, Takahiro, Kawai, Kengo, Minemura, Masami, Sugiyama, Toshiro
Format:	Online
Language:	English
Published:	S. Karger AG 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656669/

id	pubmed-3656669
recordtype	oai_dc
spelling	pubmed-36566692013-05-17 A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab Tajiri, Kazuto Tsuneyama, Koichi Miyazono, Takahiro Kawai, Kengo Minemura, Masami Sugiyama, Toshiro Published online: April, 2013 Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC. Previous studies indicated biochemical and immunological improvement in PBC after rituximab treatment. Although rituximab shows therapeutic potential for PBC, few cases have been reported and histological improvement and long-term outcome remain uncertain. Here, we report a case of PBC in a 66-year-old Japanese female patient who presented with a gastric lymphoma and who had been treated with a regimen containing rituximab for incidental malignant lymphoma. She showed biochemical and immunological improvements, and liver histology before and after rituximab treatment confirmed a decrease in liver inflammation. However, she developed liver cirrhosis a short time after rituximab treatment without biochemical or immunological worsening. Rituximab treatment for PBC might be considered and careful observation is required after treatment. S. Karger AG 2013-04-19 /pmc/articles/PMC3656669/ /pubmed/23687488 http://dx.doi.org/10.1159/000351173 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Tajiri, Kazuto Tsuneyama, Koichi Miyazono, Takahiro Kawai, Kengo Minemura, Masami Sugiyama, Toshiro
spellingShingle	Tajiri, Kazuto Tsuneyama, Koichi Miyazono, Takahiro Kawai, Kengo Minemura, Masami Sugiyama, Toshiro A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
author_facet	Tajiri, Kazuto Tsuneyama, Koichi Miyazono, Takahiro Kawai, Kengo Minemura, Masami Sugiyama, Toshiro
author_sort	Tajiri, Kazuto
title	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
title_short	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
title_full	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
title_fullStr	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
title_full_unstemmed	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
title_sort	case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab
description	Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC. Previous studies indicated biochemical and immunological improvement in PBC after rituximab treatment. Although rituximab shows therapeutic potential for PBC, few cases have been reported and histological improvement and long-term outcome remain uncertain. Here, we report a case of PBC in a 66-year-old Japanese female patient who presented with a gastric lymphoma and who had been treated with a regimen containing rituximab for incidental malignant lymphoma. She showed biochemical and immunological improvements, and liver histology before and after rituximab treatment confirmed a decrease in liver inflammation. However, she developed liver cirrhosis a short time after rituximab treatment without biochemical or immunological worsening. Rituximab treatment for PBC might be considered and careful observation is required after treatment.
publisher	S. Karger AG
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656669/
_version_	1611978609716625408

A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab

Similar Items